Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Summit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive license and collaboration agreement granting Sarepta (NASDAQ: SRPT) rights in Europe, as well as in Turkey and the Commonwealth of Independent States (‘the licensed territory’), to Summit’s utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- AK Steel (AKS) October weekly volatility increases on more puts than calls into Q3
- ARIAD Pharma (ARIA) volatility continues to move higher as shares trend lower
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Related EntitiesPre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!